FLASH SPRING SALE: 50% Off Premium Subscription >> FLASH SPRING SALE: 50% Off Premium >>
$172.36
+0 (+0%)
At Close: Dec 22, 2023
Forecast Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $172.36 $172.36 Friday, 22nd Dec 2023 RETA stock ended at $172.36. During the day the stock fluctuated 0% from a day low at $172.36 to a day high of $172.36.
90 days $172.32 $172.46
52 weeks $26.26 $172.46

Historical RETA prices

Date Open High Low Close Volume
Oct 12, 2023 $172.36 $172.36 $172.36 $172.36 0
Oct 11, 2023 $172.36 $172.36 $172.36 $172.36 0
Oct 10, 2023 $172.36 $172.36 $172.36 $172.36 0
Oct 09, 2023 $172.36 $172.36 $172.36 $172.36 0
Oct 06, 2023 $172.36 $172.36 $172.36 $172.36 0
Oct 05, 2023 $172.36 $172.36 $172.36 $172.36 0
Oct 04, 2023 $172.36 $172.36 $172.36 $172.36 0
Oct 03, 2023 $172.36 $172.36 $172.36 $172.36 0
Oct 02, 2023 $172.36 $172.36 $172.36 $172.36 0
Sep 29, 2023 $172.36 $172.36 $172.36 $172.36 0
Sep 28, 2023 $172.36 $172.36 $172.36 $172.36 0
Sep 27, 2023 $172.36 $172.36 $172.36 $172.36 0
Sep 26, 2023 $172.36 $172.36 $172.36 $172.36 0
Sep 25, 2023 $172.34 $172.46 $172.32 $172.36 1 909 215
Sep 22, 2023 $172.29 $172.33 $172.25 $172.32 661 623
Sep 21, 2023 $172.22 $172.36 $172.12 $172.17 1 887 393
Sep 20, 2023 $172.10 $172.21 $172.10 $172.21 443 586
Sep 19, 2023 $172.00 $172.15 $172.00 $172.11 339 095
Sep 18, 2023 $172.00 $172.08 $171.76 $172.05 466 023
Sep 15, 2023 $172.05 $172.15 $171.82 $172.00 788 924
Sep 14, 2023 $172.00 $172.10 $171.98 $172.06 331 846
Sep 13, 2023 $172.00 $172.10 $171.97 $172.00 1 049 691
Sep 12, 2023 $170.54 $172.05 $170.32 $171.98 1 679 766
Sep 11, 2023 $170.41 $171.12 $170.37 $170.94 1 093 294
Sep 08, 2023 $169.75 $170.36 $169.70 $170.32 545 055
Click to get the best stock tips daily for free!

About RETA

RETA Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated ... RETA Profile

Golden Star

Ticker Date Change Price
ETSY Apr 26 1.84% $67.43
DHT Apr 24 1.24% $11.28
LPLA Apr 19 2.49% $262.59
MLI Apr 19 6.77% $52.28
PFLT Apr 18 1.07% $11.25
DOOR Apr 18 0.88% $131.39
LNG Apr 17 0.644% $156.81
FCN Apr 16 2.99% $207.62
ELV Apr 16 4.26% $506.97
ITCI Apr 05 4.92% $68.44
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT